Effect of alogliptin on diavetic vascular complication

Effect of alogliptin on diavetic vascular complication - Effect of alogliptin on diavetic vascular complication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010468

Enrollment

Registered

2013-07-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

alogliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c level is above 6.5%

Exclusion criteria

Exclusion criteria: 1) insulin therapy 2)started angiotensin converting enzyme inhibitor, angiotensin receptor blocker, statin, pioglitazon within three monthes 3) pregnancy

Design outcomes

Primary

Measure	Time frame
Flow mediated vasodilatation, urinary nephrin excretion	—

Secondary

Measure	Time frame
urinary albumin excretion, estimated GFR,circulating CD34+ cell, high sensitive CRP, IL-6, small dense LDL-C	—

Countries

Japan

Contacts

Public ContactHisashi Makino

National Cerebral and cardiovascular Center Endocrinology and Metabolism

makinoh@hsp.ncvc.go.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026